Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 1, 2007, Pages 53-61

  Ikehara, Yuzuru ^a   Kojima, Naoya ^b  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Cancer metastasis; Cellular vehicles; Drug delivery system; Intraperitoneal chemotherapy; Milky spots; Omentum; Peritoneal cavity

Indexed keywords

ACTIVATED CARBON; ANTINEOPLASTIC AGENT; CARBOHYDRATE; CELL RECEPTOR; CISPLATIN; CYCLOPHOSPHAMIDE; DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; FLUOROURACIL; GLYCOLIPID; LIPOSOME; MITOMYCIN; MITOMYCIN C; NANOPARTICLE; NEOGLYCOLIPID; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BIOLOGICAL MODEL; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL THERAPY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TREATMENT FAILURE; HUMAN; HYPERTHERMIC THERAPY; LYMPHOID TISSUE; MACROPHAGE; METASTASIS; METASTASIS INHIBITION; MULTIPLE CYCLE TREATMENT; NONHUMAN; OMENTUM; OUTCOME ASSESSMENT; OVARY CANCER; REVIEW; STOMACH CANCER; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MACROPHAGES, PERITONEAL; MANNOSE; PERITONEAL NEOPLASMS;

EID: 33947310418     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Vital statistics in Japan, 1958-2004. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labour and Welfare of Japan.
2. Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: New management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol (2004) 5(4):219-228.
3. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ: Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol (2004) 22(12):2395-2403.
4. Cannistra SA: Intraperitoneal chemotherapy comes of age. N Engl J Med (2006) 354(1):77-79. •• This paper is a comment on reference [5], and reviews intraperitoneal chemotherapy on ovarian cancer.
5. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 62(4):1-11.
6. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med (1996) 335(4):1950-1955.
7. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, Green M: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med (1982) 97(6):845-851.
8. Goel R, Cleary SM, Horton C, Kirmani S, Abramson I, Kelly C, Howell SB: Effect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst (1989) 81(20):1552-1560.
9. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med (2006) 354(1):34-43. • This paper reports supporting evidence for the application of intraperitoneal chemotherapy for stage III ovarian cancer patients who undergo optimal surgical cytoreduction.
10. Fujiwara K, Markman M, Morgan M, Coleman RL: Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2005) 97(1):10-15.
11. Casper ES, Kelsen DP, Alcock NW, Lewis JL Jr: Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep (1983) 67(3):235-238.
12. Singhal P, Lele S: Intraperitoneal chemotherapy for ovarian cancer: Where are we now? J Natl Compr Canc Netw (2006) 4(9):941-946. •• The National Cancer Institute announced recommendations that women with stage III ovarian cancer who undergo optimal surgical cytoreduction should be considered for intraperitoneal chemotherapy.
13. Yonemura Y, Endo Y, Obata T, Sasaki T: Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci (2007) 98(1):11-18. • A valuable introduction to intraperitoneal metastases of gastric cancer, molecular mechanisms and recent advances in the treatment of peritoneal dissemination.
14. Yonemura Y, Bandou E, Kinoshita K, Kawamura T, Takahashi S, Endou Y, Sasaki T: Effective therapy for peritoneal dissemination in gastric cancer. Surg Oncol Clin N Am (2003) 12(3):635-648.
15. Ohashi N, Kodera Y, Nakanishi H, Yokoyama H, Fujiwara M, Koike M, Hibi K, Nakao A, Tatematsu M: Efficacy of intraperitoneal chemotherapy with paclitaxel targeting peritoneal micrometastasis as revealed by GFP-tagged human gastric cancer cell lines in nude mice. Int J Oncol (2005) 27(3):637-644.
16. Hagiwara A, Takahashi T, Sawai K, Taniguchi H, Shimotsuma M, Okano S, Sakakura C, Tsujimoto H, Osaki K, Sasaki S, Shirasu M: Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice. Cancer Res (1993) 53(3):687-692.
17. Krist LF, Kerremans M, Broekhuis-Fluitsma DM, Eestermans IL, Meyer S, Beelen RH: Milky spots in the greater omentum are predominant sites of local tumour cell proliferation and accumulation in the peritoneal cavity. Cancer Immunol Immunother (1998) 47(4):205-212.
18. Nakanishi H, Ito S, Mochizuki Y, Tatematsu M: Evaluation of chemosensitivity of micrometastases with green fluorescent protein gene-tagged tumor models in mice. Methods Mol Med (2005) 111:351-362.
19. Steinberg JJ, Demopoulos RI, Bigelow B: The evaluation of the omentum in ovarian cancer. Gynecol Oncol (1986) 24(3):327-330.
20. Sakakura C, Hagiwara A, Shirasu M, Yasuoka R, Fujita Y, Nakanishi M, Aragane H, Masuda K, Shimomura K, Abe T, Yamagishi H: Polymerase chain reaction for detection of carcinoembryonic antigen-expressing tumor cells on milky spots of the greater omentum in gastric cancer patients: A pilot study. Int J Cancer (2001) 95(5):286-289.
21. Janik P, Dabrowski M, Dux K: Dynamics of growth and regression of Ehrlich ascites carcinoma transplanted intraperitoneally in rats. Arch Immunol Ther Exp (Warsz) (1966) 14(6):717-723.
22. Dux K: Role of the greater omentum in the immunological response of mice and rats to the intraperitoneal inoculation of Ehrlich ascites tumor. Arch Immunol Ther Exp (Warsz) (1969) 17(4):425-432.
23. Lawrance RJ, Loizidou M, Cooper AJ, Alexander P, Taylor I: Importance of the omentum in the development of intra-abdominal metastases. Br J Surg (1991) 78(1):117-119.
24. Recklinghausen F: Uber Eiter und Bindesgewebs-korperchen. Vir Arch Pathol Anat (1863) 28(4):157-166.
25. Mandache E, Moldoveanu E, Savi G: The involvement of omentum and its milky spots in the dynamics of peritoneal macrophages. Morphol Embryol (Bucur) (1985) 31(2):137-142.
26. Dullens HF, Rademakers LH, Cluistra S, Van Os R, Dux K, Den Besten PJ, Den Otter W: Parathymic lymph nodes during growth and rejection of intraperitoneally inoculated tumor cells. Invasion Metastasis (1991) 11(4):216-226.
27. Hodel C: Ultrastructural studies on the absorption of protein markers by the greater omentum. Eur Surg Res (1970) 2(6):435-449.
28. Hagiwara A, Takahashi T, Kojima O, Sawai K, Yamaguchi T, Yamane T, Taniguchi H, Kitamura K, Noguchi A, Seiki K, Sakakura C: Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet (1992) 339(8794):629-631. • This study reports that intraperitoneal treatment with carbon-adsorbed mitomycin seems to improve survival after gastrectomy for gastric cancer, presumably by a prophylactic effect on peritoneal recurrence.
29. Horwitz DA, Allison AC, Ward P, Kight N: Identification of human mononuclear leucocyte populations by esterase staining. Clin Exp Immunol (1977) 30(2):289-298.
30. Wilkosz S, Ireland G, Khwaja N, Walker M, Butt R, de Giorgio-Miller A, Herrick SE: A comparative study of the structure of human and murine greater omentum. Anat Embryol (Berl) (2005) 209(3):251-261.
31. Inoue N, Otsuki Y: Lymphocyte subpopulations in mediastinal milky spots of mice: Light- and electron-microscopic immunohistochemical observations. Arch Histol Cytol (1992) 55(1):89-96.
32. Cui L, Johkura K, Liang Y, Teng R, Ogiwara N, Okouchi Y, Asanuma K, Sasaki K: Biodefense function of omental milky spots through cell adhesion molecules and leukocyte proliferation. Cell Tissue Res (2002) 310(3):321-330.
33. Oosterling SJ, van der Bij GJ, Bogels M, van der Sijp JR, Beelen RH, Meijer S, van Egmond M: Insufficient ability of omental milky spots to prevent peritoneal tumor outgrowth supports omentectomy in minimal residual disease. Cancer Immunol Immunother (2006) 55(9):1043-1051. • This study demonstrated that omental milky spots are insufficient to prevent intra abdominal tumor outgrowth in animal models. Omentectomy is recommended in surgical treatment of intraabdominal tumors that are prone to disseminate intraperitoneally.
34. Sobin LH, Fleming ID: TNM classification of malignant tumors fifth edition (1997) Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer (1997) 80(9):1803-1804.
35. Hermanek P: Disseminated tumor cells versus micrometastasis: Definitions and problems. Anticancer Res (1999) 19(4A):2771- 2774.
36. Sobin LH: TNM: Evolution and relation to other prognostic factors. Semin Surg Oncol (2003) 21(1):3-7.
37. Sobin LH: TNM, sixth edition: New developments in general concepts and rules. Semin Surg Oncol (2003) 21(1):19-22.
38. Kurebayashi J, Nukatsuka M, Fujioka A, Saito H, Takeda S, Unemi N, Fukumori H, Kurosumi M, Sonoo H, Dickson RB: Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clin Cancer Res (1997) 3(5):653-659.
39. Nakanishi H, Mochizuki Y, Kodera Y, Ito S, Yamamura Y, Ito K, Akiyama S, Nakao A, Tatematsu M: Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci (2003) 94(1):112-118.
40. Kienle P, Koch M, Autschbach F, Benner A, Treiber M, Wannenmacher M, von Knebel Doeberitz M, Buchler M, Herfarth C, Weitz J: Decreased detection rate of disseminated tumor cells of rectal cancer patients after preoperative chemoradiation: A first step towards a molecular surrogate marker for neoadjuvant treatment in colorectal cancer. Ann Surg (2003) 238(3):324-330; discussion 330-331.
41. Lee CM, Tanaka T, Murai T, Kondo M, Kimura J, Su W, Kitagawa T, Ito T, Matsuda H, Miyasaka M: Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo. Cancer Res (2002) 62(15):4282-4288.
42. Iinuma H, Maruyama K, Okinaga K, Sasaki K, Sekine T, Ishida O, Ogiwara N, Johkura K, Yonemura Y: Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer (2002) 99(1):130-137.
43. Mamot C, Ritschard R, Kung W, Park JW, Herrmann R, Rochlitz CF: EGFR-targeted immunoliposomes derived from the monoclonal antibody EMD72000 mediate specific and efficient drug delivery to a variety of colorectal cancer cells. J Drug Target (2006) 14(4):215-223.
44. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW: Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res (2003) 63(12):3154-3161.
45. Rosen HR, Jatzko G, Repse S, Potrc S, Neudorfer H, Sandbichler P, Zacherl J, Rabl H, Holzberger P, Lisborg P, Czeijka M: Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: Results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology. J Clin Oncol (1998) 16(8):2733-2738. • This study reports that adjuvant intraperitoneal therapy of gastric cancer by mitomycin bound to activated carbon particles has no benefit for prognosis following radical resection of locally advanced gastric cancer in a randomized multicenter phase III trial.
46. Hagiwara A, Sakakura C, Tsujimoto H, Ohgaki M, Imanishi T, Yamazaki J, Sawai K, Takahashi T, Yamamoto A, Muranishi S, Tabta Y, Ikada Y: New formulation of 5-fluorouracil in microspheres reduces toxicity in mice. Anticancer Drugs (1996) 7(7):780-784.
47. Fujiyama J, Nakase Y, Osaki K, Sakakura C, Yamagishi H, Hagiwara A: Cisplatin incorporated in microspheres: Development and fundamental studies for its clinical application. J Control Release (2003) 89(3):397-408.
48. Ikehara Y, Niwa T, Biao L, Ikehara SK, Ohashi N, Kobayashi T, Shimizu Y, Kojima N, Nakanishi H: A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res (2006) 66(17):8740-8748. •• Coating oligomannose residues (mannotriose; Man3) onto OMLs led to significant improvement in the specificity and efficiency of uptake by macrophages, and that intracellular hyperthermia - achieved by using magnetic nanoparticles encased in the OMLs and an alternating magnetic field - could control the release of the components carried from the macrophages.
49. Pereboeva L, Curiel DT: Cellular vehicles for cancer gene therapy: Current status and future potential. BioDrugs (2004) 18(6):361-385. •• This excellent review provides an introduction to cellular vehicles, a method to study cellular vehicles and a detailed account of how cellular vehicles can be used in cancer gene therapy.
50. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res (2002) 62(13):3603-3608. • This paper provides the first demonstration of MSCs as a platform for delivery of biological agents in tumors.
51. Nakamizo A, Marini F, Amano T, Khan A, Studeny M, Gumin J, Chen J, Hentschel S, Vecil G, Dembinski J, Andreeff M, Lang FF: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res (2005) 65(8):3307-3318.
52. Studeny M, Marini FC, Dembinski JL, Zompetta C, Cabreira-Hansen M, Bekele BN, Champlin RE, Andreeff M: Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 96(21):1593-1603. •• This study demonstrated that MSCs are an effective platform for the targeted delivery of therapeutic proteins to cancer sites. Injected MSC-IFNβ cells suppressed the growth of pulmonary metastases, presumably through the local production of IFNβ in the tumor microenvironment.
53. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science (1997) 276(5309):71-74.
54. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential of adult human mesenchymal stem cells. Science (1999) 284(5411):143-147.
55. Le Blanc K, Pittenger M: Mesenchymal stem cells: Progress toward promise. Cytotherapy (2005) 7(1):36-45.
56. Pereboeva L, Komarova S, Mikheeva G, Krasnykh V, Curiel DT: Approaches to utilize mesenchymal progenitor cells as cellular vehicles. Stem Cells (2003) 21(4):389-404.
57. Komarova S, Kawakami Y, Stoff-Khalili MA, Curiel DT, Pereboeva L: Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 5(3):755-766.
58. Burke B, Sumner S, Maitland N, Lewis CE: Macrophages in gene therapy: Cellular delivery vehicles and in vivo targets. J Leukocyte Biol (2002) 72(3):417-428. •• This intriguing review introduces methods to transfer genes to macrophages, and provides a detailed account of how macrophages as cellular vehicles can be used in cancer gene therapy.
59. Burke B: Macrophages as novel cellular vehicles for gene therapy. Expert Opin Biol Ther (2003) 3(6):919-924.
60. Pastorino S, Massazza S, Cilli M, Varesio L, Bosco MC: Generation of high-titer retroviral vector-producing macrophages as vehicles for in vivo gene transfer. Gene Ther (2001) 8(6):431-441.
61. Mizuochi T, Loveless RW, Lawson AM, Chai W, Lachmann PJ, Childs RA, Thiel S, Feizi T: A library of oligosaccharide probes (neoglycolipids) from N-glycosylated proteins reveals that conglutinin binds to certain complex-type as well as high mannose-type oligosaccharide chains. J Biol Chem (1989) 264(23):13834-13839.
62. Nakanishi H, Kodera Y, Tatematsu M: Molecular method to quantitatively detect micrometastases and its clinical significance in gastrointestinal malignancies. Adv Clin Chem (2004) 38:87-110.